Johnson & Johnson announced promising Phase 1 results for a novel immunotherapy combining pasritamig and JNJ-9401, targeting two prostate cancer proteins to activate T cells. In the trial, 73% of patients saw PSA levels drop by at least 50%, with nearly half achieving reductions of 90% or more, and no severe treatment-related side effects reported. This dual-antigen approach could offer a new outpatient treatment option for metastatic castration-resistant prostate cancer, a condition with limited therapies and poor prognosis. The combination is now advancing to a larger Phase 3 study to confirm its benefits.
Johnson & Johnson shares are trading near their 52-week high, priced at USD 276.22 as of Nov 08, 2026 23:02 WIB, just below the peak of USD 278.43. The stock has gained 1.43% in the past day, reflecting steady investor interest. On Pluang, buying and selling activity is nearly balanced with 51% of orders to buy and 49% to sell, indicating cautious optimism around the health sector giant amid its promising immunotherapy news.
Three dividend stocks from healthcare, real estate, and energy sectors—Johnson & Johnson, Realty Income, and Chevron—stand out for their reliable dividends supported by strong cash flow and manageable debt. Johnson & Johnson boasts 64 years of consec...
Johnson & Johnson announced new patient data from the Phase 2 DAHLIAS study showing nipocalimab significantly improves mouth dryness, the most impactful symptom for Sjögren's disease patients. The drug also increased saliva production by 50% in more ...
Johnson & Johnson announced positive Phase 3 trial results for ICOTYDE (icotrokinra), an oral peptide targeting IL-23R, in treating biologic-naïve adults with active psoriatic arthritis. At 16 weeks, 58% of patients achieved ACR20 response versus 41%...
As of late 2026, the average 1-year certificate of deposit (CD) rate stands at 1.76%, below the Federal Reserve's target range. Some investors are considering blue-chip dividend stocks like Microsoft, Johnson & Johnson, and Coca-Cola, which offer pot...
The FDA granted accelerated approval to Johnson & Johnson's RYBREVANT FASPRO, a dual-targeted therapy for adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have progressed after platinum-based chemotherapy and anti...
